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ABSTRACT
A transdermal delivery system containing the anti-inflammatory analgesic diclo-
fenac diethyl ammonium in an ethyl hexyl acrylate and vinyl acetate pressure-sensi-
tive adhesive system was developed for percutaneous absorption. These patches
were subjected to in vitro permeation and permeation enhancement studies through
rat skin using a specially designed diffusion cell. Further, the work deals with percu-
taneous absorption studies carried out on both animals and human volunteers. The
pharmacokinetic parameters calculated from the blood levels of the drug reveal a
profile typical of a sustained-release formulation, with the ability to maintain ade-
quate plasma levels for 24 hr (i.e., up to the next application). (Area under the curve
[AUC]: 4.356 6 1.3 mcg/ml.hr in animals and 0.442 6 0.053 mcg/ml.hr in humans;
Tmax was 8 hr in both the cases, whereas Cmax was 0.288 6 0.088 mcg/ml in animals
and 0.034 6 .008 mcg/ml in human volunteers.) The amount of the drug bioavaila-
ble for targeting the sites of action is lower than via the oral route, but the absorbed
dose appears to be adequate for therapeutic use, particularly because of the absence
of side effects.
* To whom correspondence should be addressed.
695
Copyright Ó 1999 by Marcel Dekker, Inc. www.dekker.com
D
ru
g 
D
ev
el
op
m
en
t a
nd
 In
du
str
ia
l P
ha
rm
ac
y 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f S
as
ka
tc
he
w
an
 o
n 
07
/0
4/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
696 Devi and Paranjothy
INTRODUCTION
Transdermal drug delivery has the advantage of being
both precise and consistent, like a closely monitored in-
travenous drip, but it is noninvasive because there is no
needle involved. Diclofenac diethyl ammonium is a non-
steroidal anti-inflammatory drug (NSAID) used for the
symptomatic relief of pain and inflammation in patients
suffering from musculoskeletal diseases. In recent years,
there has been an increasing interest in the development
of anti-inflammatory drugs for topical usage. It has been
recorded in literature that diclofenac, when applied
topically, penetrates the skin barrier in an amount suf-
ficient to exert the desired level of local therapeutic ac-
tivity (1,2).
In contrast to conventional formulations (cream, gel,
ointment, etc.), the diclofenac diethyl ammonium trans-
dermal patch permits, by occlusive bandage and slow re-
lease of the drug, a constant and continuous presence of
the active ingredient at the inflamed area.
For the practical use of the newly developed diclo-
fenac transdermal patches in human therapy, in vitro
evaluation and pharmacokinetic studies needed to be per-
formed in both animals and human volunteers.
MATERIALS AND METHODS
Diclofenac diethyl ammonium (a kind gift by BPRL,
Bangalore, India); polyvinyl pyrrolidone [S.D. Fine
Chemicals(P) Ltd., Bombay, India]; propylene glycol
(Qualigens, Mumbai, India); chloroform, methanol, and
acetonitrile of high-performance liquid chromatography
(HPLC) grade (Ranbaxy Labs, New Delhi, India); and
ethyl hexyl acrylate and vinyl acetate, which is an adhe-
sive film former (3M Silicones, New York). This adhe-
sive film former was nontoxic and nonabsorbable and did
not lose its adhesive properties when formulated with the
drugs and excipients. All the other chemicals used in the
study were of analytic reagent grade.
Preparation of the Transdermal Patches
For preparation of the transdermal patches, 300 mg of
the acrylate adhesive was dissolved in 5 ml chloroform,
followed by 400 mg polyvinyl pyrrolidone, which was
also dissolved in the adhesive solution by slow stirring.
Then, 360 mg of the drug was added to the clear solution
and stirred slowly under covered conditions until it com-
pletely dissolved. Propylene glycol (0.4 ml) and metha-
nol (1.6 ml) were finally added and stirred well to get a
clear solution.
Next, 1.2 ml of the casting solution was pipetted onto
the center of stainless steel rings with smooth surfaces
and placed on the backing layer of pearlescised polyester
so that it formed a well. The solution was dried at room
temperature for 24 hr. Patches with a 5-cm diameter con-
taining 60 mg of the drug uniformly distributed in the
adhesive were cut. These patches were covered with sili-
cone-coated paper as a covering liner and were stored for
further evaluation.
In Vitro Skin Permeation and Permeation
Enhancement Studies
Freshly excised albino rat abdominal skin was used
as the permeation barrier. A diffusion cell was fabricated
on the lines of a Keshary Chein cell (3) to carry out in
vitro evaluation (Fig. 1).
The skin section and the patch were mounted carefully
between the donor and receptor compartments of the dif-
fusion cell and held securely by springs. The donor com-
partment was empty and open to the atmosphere, but the
receptor compartment was filled with distilled water (65
ml). The temperature of the diffusion cells was main-
Figure 1. Diffusion cell for in vitro evaluation.
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tained at 32° C by immersion in a water bath with sides
that were insulated and which had a thermostat. The cells
were continuously agitated. Samples were withdrawn
from the receptor compartments at predetermined inter-
vals and replaced with fresh receptor medium. The sam-
ples were analyzed spectroscopically at 450 nm after suit-
able dilution.
To optimize the penetration, and hence the absorption,
of the drug from the transdermal patches, penetration en-
hancers were used. They included oleic acid, propylene
glycol, dimethyl sulfoxide, hexane, and ethanol. These
enhancers were used in two different ways: (a) by inclu-
sion into the patches at a concentration of 5% w/v (4)
and (b) by treating the freshly excised rat abdominal skin
on the stratum corneum side with 2 ml of the enhancer
individually or with a combination of enhancers (5).
Results obtained are presented graphically in Graph 1
and Graph 2.
Pharmacokinetic Evaluation of the Patches
in Animals
Rabbits have been used as models for bioavailability
studies among the various animal models. The experi-
ment was conducted on six rabbits weighing between 1.8
and 2.0 kg. Before commencement of the experiment, the
skin of every rabbit was thoroughly examined for any
abnormality, and only those having no structural abnor-
mality of the skin were included.
A skin area of around 50 cm2 was shaved, covering
both sides of the vertebral column of each rabbit, and
Graph 1. Effect of penetration enhancers on the in vitro per-
meation of diclofenac diethyl ammonium.
Graph 2. Effect of solvent treatment and its duration on the
in vitro permeation of diclofenac diethyl ammonium. A, no en-
hancer; B, DMSO (1 hr); C, ethanol 1 hexane (1 hr); D, ethanol
1 hexane 1 propylene glycol (1 hr); E, ethanol 1 hexane 1
propylene glycol (1/2 hr); F, ethanol 1 hexane 1 propylene gly-
col (10 min).
care was taken to avoid damage to skin during shaving.
Before application of the patches, rabbits were kept for
24 hr under observation for any untoward effect of shav-
ing to the skin and were fasted over this period. The
patches containing 60 mg of diclofenac diethyl ammo-
nium were applied on the shaved surface.
Next, 2 ml blood was withdrawn from the ear vein of
each rabbit at 0, 4, 8, 12, and 24 hr intervals into heparin-
ized tubes to prevent the coagulation of blood. Due to
the small size of the animal and damage to the ear vein,
it was not possible to withdraw the blood for more than
the above-mentioned intervals (6).
Blood samples were centrifuged for 30 min at 5000
rpm, and the plasma was separated and kept in the refrig-
erator until analysis by the standardized HPLC proce-
dure. The blood levels of the drugs obtained are recorded
in Graph 3.
Pharmacokinetic Evaluation of the Patches
in Human Volunteers
The study was conducted in six healthy male volun-
teers, aged between 21 and 23 years, and weighing about
50–60 kg. Drug administration and blood withdrawal
were carried out under the direct supervision of a doctor
and with the assistance of a trained medical laboratory
technician. The volunteers were asked to abstain from
any drug or alcohol for 1 week and were deprived of food
for 12 hr prior to the study.
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Graph 3. Blood levels of diclofenac diethyl ammonium from
transdermal patches in rabbits.
The transdermal patches containing 60 mg of diclo-
fenac were applied on the anterior surface of the forearm,
near the elbow. The volunteers were instructed not to re-
move the patch and also to observe for any sign of irrita-
tion at the site of application. Blood samples (10 ml) were
collected with the help of a syringe, which was rinsed
with a dilution of heparin into heparinized tubes at time
intervals of 0, 4, 8, 12, and 24 hr after application of the
patch. The plasma was immediately separated by centrif-
ugation for 30 min at 5000 rpm and stored in the refriger-
ator for further analysis.
The drug in the plasma was analyzed by HPLC, and
the blood levels obtained are recorded in Graph 4.
Graph 4. Blood levels of diclofenac diethyl ammonium from
transdermal patches in human volunteers.
High-Pressure Liquid Chromatographic
Analysis
The animal and human blood samples were analyzed
for drug content by an HPLC method (7). A high-perfor-
mance liquid chromatograph equipped with a SPD-10A
UV-Vis detector, LC-10AD pump, and a C-R7A Plus In-
tegrator from Shimadzu-Japan was used for the drug
analyses. A C18 column was used. The plasma proteins
were precipitated with 5 M hydrochloric acid. A pinch
of sodium chloride was added to each tube to prevent
emulsification during the extraction process. The sample
was vortexed with 5 ml ethyl acetate for 5 min. The or-
ganic layer was separated by centrifugation at 2000 rpm
for 10 min and dried in vacuum. The residue was recon-
stituted with the mobile phase (0.1 ml) and injected (20
m l) into the column. The analysis was carried out at a
wavelength of 274 nm. A mixture of methanol, acetoni-
trile, and water (40:40:25) was used as the mobile phase
at a flow rate of 1.5 ml per min. The concentrations of
samples were calculated from a standard graph (200 ng/
ml–1000 ng/ml concentration range) prepared from peak
area versus concentrations of diclofenac.(r 5 .990).
Statistical Analysis
All the in vitro data are reported as mean 6 SD of
the mean. The in vivo data (i.e., animal and human blood
levels) were tested for statistical significance using analy-
sis of variance (ANOVA) and were found to be signifi-
cant on the basis of the F value (p , .01).
Serial No. Study F value
1 Diclofenac diethyl ammonium in F (3,20) 7.900
animals
2 Diclofenac diethyl ammonium in F (3,20) 20.756
humans
Adverse Reactions
The animals and the human volunteers were kept un-
der close observation for any adverse effect that occurred
during the study, which were reported as to the time of
onset, nature, duration, and severity.
RESULTS
The in vitro mean cumulative percentage permeation
versus time profiles of diclofenac were linear, which indi-
cates zero-order kinetics of drug permeation (Graph 1).
It is also clear from Graph 1 that the amount of drug that
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Table 1
Mean Pharmacokinetic Parameters of Diclofenac Diethyl Ammonium
Mean 6 SD in Mean 6 SD in
Sl. No. Parameters Rabbits Humans
1 Cmax (mcg/ml) 0.288 6 0.088 0.034 6 0.008
2 Tmax (hours) 8.000 6 0.000 8.000 6 0.000
3 Ke (hour21) 0.144 6 0.020 0.070 6 0.006
4 t1/2 (hr) 4.893 6 0.800 9.966 6 0.834
5 AUC (0 fi 24) mcg/ml.hr 4.356 6 1.300 0.442 6 0.053
6 AUC (0 fi ~) mcg/ml.hr 5.663 6 1.656 0.637 6 0.084
7 MRT (hr) 11.462 6 2.409 15.388 6 0.426
permeated through the rat skin from the plain patch (no
enhancement technique employed) was rather low;
hence, permeation-enhancement techniques have to be
employed to enhance the permeation. Although a moder-
ate increase in permeation of the drug was brought about
by incorporating the enhancers in the patch, a definite
increase in the permeation was exhibited on treating the
skin on the stratum corneum side with a solvent mixture.
The maximum enhancement was around 7.5-fold,
brought about by a hexane/ethanol/propylene glycol sol-
vent mixture; this increase in permeation was propor-
tional to the duration of solvent treatment.
From the percutaneous absorption studies, various
pharmacokinetic parameters (8) of the drug were calcu-
lated (Table 1). Excellent correlation was observed be-
tween the animal and human volunteer studies. Measur-
able concentrations of diclofenac diethyl ammonium
were obtained in the plasma from the fourth hour in ani-
mals and also in human volunteers. The concentration of
the drug reached the maximum at the eighth hour; a Cmax
of 0.034 m g/ml was obtained for humans, and a Cmax of
0.288 m g/ml was obtained for animals (rabbits). Thereaf-
ter, the concentration of the drug reduced gradually, but
even at the 24th hour, measurable quantities of diclofenac
persisted in both animals and humans.
The area-under-the-curve (AUC) values (which more
correctly define bioavailability), calculated using the
trapezoidal rule, indicated an extent of drug availability
of 4.356 m g/ml.hr of diclofenac from the transdermal
dosage form in rabbits compared to 0.442 m g/ml.hr in
the human volunteers.
The elimination rate constant Ke calculated from the
linear terminal elimination phase was found to be 0.144/
hr for diclofenac in rabbits compared to 0.070/hr in hu-
mans.
The calculated parameters also indicate that the bio-
logical half-life of diclofenac is prolonged from 2 hr
(conventional tablets) to 4.9 hr in animals and to 9.9 hr
in human volunteers; hence, the drug administered in the
transdermal dosage form will remain in the body for a
longer period and thus will exert a sustained action.
DISCUSSION
Regression analysis of the in vitro (Graphs 1 and 2)
permeation curves was carried out, and the slope of the
straight line was obtained after plotting; the mean cumu-
lative amount permeated per patch ( m g/mg) versus time
was taken as the experimental skin flux for diclofenac
diethyl ammonium. The cumulative mean flux values of
diclofenac from the patch, which was subjected to in vitro
permeation studies after treating the rat skin with the
hexane/ethanol/propylene glycol solvent system, was
54.78 m g/cm2/hr was significantly higher than that ob-
tained with the plain patch, which was 6.88 m g/cm2/hr.
Thus, it can be concluded that the drug diclofenac per-
meates the skin when administered transdermally and
attains measurable concentrations in the bloodstream
within 4 hr. Since this dosage form can be administered
at the site of action itself, the drug not only permeates
the skin and reaches the systemic circulation, but also
concentrates itself at the site of action; hence, it is possi-
ble to achieve maximum pharmacological effects with
minimum quantities of the drug, thus making it possible
to reduce the dose administered through this route with
a concomitant reduction in side effects associated with
the drug.
The patches did not show any signs of erythema,
edema, necrosis, ulceration, or pigmentation in both ani-
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mal and human volunteer studies. The above safety data
obtained indicate that the transdermal patch of diclofenac
diethyl ammonium has a very good local tolerability in
both animals and humans, while there is no need to deal
with possible adverse systemic effects.
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